Medicare Drug Discounts: Ensuring Access to Plasma-Derived Specialty Medicines.
This law introduces specific, phased-in rules for manufacturer discounts on life-saving, plasma-derived drugs within the Medicare Part D program. The goal is to ensure that Medicare beneficiaries maintain consistent access to these critical specialty biological products. The change affects how discounted prices are calculated, depending on whether the patient has met their annual out-of-pocket drug spending limit.
Key points
Establishes a special, phased-in discount structure for manufacturers of biological drugs derived from human plasma.
The change aims to protect access to critical specialty medicines for individuals enrolled in Medicare.
The calculation of the discounted drug price will depend on whether the patient has exceeded the annual out-of-pocket threshold for Part D drugs.
Expired
Citizen Poll